Companies Dominating the Subdermal Contraceptive Implants Market
- Merck & Co., Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Shanghai Dahua Pharmaceutical Co., Ltd,
- Bayer AG
- Wyeth Pharmaceuticals
- Baxter
- Gerresheimer AG
- Theramex
- Contraline, Inc.
- Pfizer, Inc.
- Novartis AG
- Schott AG
- Eli Lilly and Company
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
Browse Key Market Insights with Data Illustration:
In the News
- Shanghai Dahua Pharmaceutical Co., Ltd, along with DKT WomanCare announced to reduce the price of, a two-rod contraceptive implant Levoplant that was recently approved to enhance women's reproductive health autonomy. Furthermore, it will now cost qualified buyers around USD 6 which will aid in increasing access to a high-quality contraceptive for those who need it the most and will make it easier for people who require access to quality contraception.
- Contraline, Inc. announced to investment of over USD 7 million for the creation of the first injectable hydrogel-based implanted male contraceptives to create a long-acting, reversible male contraceptive that gives more individuals more choices for family planning and changes how people think about contraception.
- Teva Pharmaceutical Industries Ltd. introduced a Generic Version of NuvaRing intended for use by women of reproductive age that combines estrogen and progestin to prevent conception. Furthermore, the product is an essential addition to Teva's generic product line which must be worn for three weeks.
